FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2151909535> ?p ?o ?g. }

• W2151909535 endingPage "72" @default.
• W2151909535 startingPage "1666" @default.
• W2151909535 abstract "Tetrathiomolybdate (TM), a copper-lowering agent, has been shown in preclinical murine tumor models to be antiangiogenic. We evaluated the antitumor activity of TM in patients with advanced kidney cancer in a Phase II trial.Fifteen patients with advanced kidney cancer were eligible to participate in this trial. TM was initiated p.o. at 40 mg three times a day with meals and 60 mg at bedtime to deplete copper. A target serum ceruloplasmin (CP) level of 5-15 mg/dl was defined as copper depletion. Doses of TM were reduced for grade 3-4 toxicity and to maintain a CP level in the target range. Once copper depletion was attained, patients underwent baseline tumor measurements and then again every 12 weeks for response assessment. Patients not exhibiting progressive disease at 12 weeks after copper depletion continued on treatment. Serum levels of Interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) were assayed pretreatment and at various time points on treatment. Dynamic contrast enhanced-magnetic resonance imaging (DCE-MRI) was performed on selected patients in an attempt to assess changes in tumor vascularity.All of the patients rapidly became copper depleted. Thirteen patients were evaluable for response. No patient had a complete response or PR. Four patients (31%) had stable disease for at least 6 months during copper depletion (median, 34.5 weeks). TM was well tolerated, with dose reductions most commonly occurring for grade 3-4 granulocytopenia of short duration not associated with febrile episodes. Serum levels of IL-6, IL-8, VEGF, and bFGF did not correlate with clinical activity. Serial DCE-MRI was performed only in four patients, and a decrease in vascularity seemed to correlate with necrosis of a tumor mass associated with tumor growth.TM is well tolerated and consistently depletes copper as measured by the serum CP level. Clinical activity was limited to stable disease for a median of 34.5 weeks in this Phase II trial in patients with advanced kidney cancer. Serum levels of proangiogenic factors IL-6, IL-8, VEGF, and bFGF may correlate with copper depletion but not with disease stability in this small cohort. TM may have a role in the treatment of kidney cancer in combination with other antiangiogenic therapies." @default.
• W2151909535 created "2016-06-24" @default.
• W2151909535 creator A5012994230 @default.
• W2151909535 creator A5021595416 @default.
• W2151909535 creator A5024602864 @default.
• W2151909535 creator A5045488672 @default.
• W2151909535 creator A5059500199 @default.
• W2151909535 creator A5059567824 @default.
• W2151909535 creator A5071608210 @default.
• W2151909535 creator A5071917673 @default.
• W2151909535 date "2003-05-01" @default.
• W2151909535 modified "2023-10-03" @default.
• W2151909535 title "Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer." @default.
• W2151909535 cites W121642688 @default.
• W2151909535 cites W1514961004 @default.
• W2151909535 cites W1518373859 @default.
• W2151909535 cites W1918337600 @default.
• W2151909535 cites W1969194948 @default.
• W2151909535 cites W1983761594 @default.
• W2151909535 cites W1997878621 @default.
• W2151909535 cites W2010160635 @default.
• W2151909535 cites W2016859917 @default.
• W2151909535 cites W2022970217 @default.
• W2151909535 cites W2029245342 @default.
• W2151909535 cites W2029409133 @default.
• W2151909535 cites W2039530430 @default.
• W2151909535 cites W2040200331 @default.
• W2151909535 cites W2042098439 @default.
• W2151909535 cites W2061350341 @default.
• W2151909535 cites W2072626310 @default.
• W2151909535 cites W2095454306 @default.
• W2151909535 cites W2101160504 @default.
• W2151909535 cites W2106059645 @default.
• W2151909535 cites W2118775158 @default.
• W2151909535 cites W2140496726 @default.
• W2151909535 cites W2141577422 @default.
• W2151909535 cites W2141851994 @default.
• W2151909535 cites W2143813821 @default.
• W2151909535 cites W2152349142 @default.
• W2151909535 cites W2161656272 @default.
• W2151909535 cites W2163559464 @default.
• W2151909535 cites W2464595280 @default.
• W2151909535 cites W83138054 @default.
• W2151909535 cites W97251553 @default.
• W2151909535 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12738719" @default.
• W2151909535 hasPublicationYear "2003" @default.
• W2151909535 type Work @default.
• W2151909535 sameAs 2151909535 @default.
• W2151909535 citedByCount "53" @default.
• W2151909535 countsByYear W21519095352012 @default.
• W2151909535 countsByYear W21519095352014 @default.
• W2151909535 countsByYear W21519095352015 @default.
• W2151909535 countsByYear W21519095352016 @default.
• W2151909535 countsByYear W21519095352017 @default.
• W2151909535 countsByYear W21519095352018 @default.
• W2151909535 countsByYear W21519095352019 @default.
• W2151909535 countsByYear W21519095352020 @default.
• W2151909535 countsByYear W21519095352021 @default.
• W2151909535 countsByYear W21519095352022 @default.
• W2151909535 countsByYear W21519095352023 @default.
• W2151909535 crossrefType "journal-article" @default.
• W2151909535 hasAuthorship W2151909535A5012994230 @default.
• W2151909535 hasAuthorship W2151909535A5021595416 @default.
• W2151909535 hasAuthorship W2151909535A5024602864 @default.
• W2151909535 hasAuthorship W2151909535A5045488672 @default.
• W2151909535 hasAuthorship W2151909535A5059500199 @default.
• W2151909535 hasAuthorship W2151909535A5059567824 @default.
• W2151909535 hasAuthorship W2151909535A5071608210 @default.
• W2151909535 hasAuthorship W2151909535A5071917673 @default.
• W2151909535 hasConcept C121608353 @default.
• W2151909535 hasConcept C126322002 @default.
• W2151909535 hasConcept C126894567 @default.
• W2151909535 hasConcept C141071460 @default.
• W2151909535 hasConcept C2778653478 @default.
• W2151909535 hasConcept C28452662 @default.
• W2151909535 hasConcept C29730261 @default.
• W2151909535 hasConcept C31760486 @default.
• W2151909535 hasConcept C71924100 @default.
• W2151909535 hasConcept C90924648 @default.
• W2151909535 hasConceptScore W2151909535C121608353 @default.
• W2151909535 hasConceptScore W2151909535C126322002 @default.
• W2151909535 hasConceptScore W2151909535C126894567 @default.
• W2151909535 hasConceptScore W2151909535C141071460 @default.
• W2151909535 hasConceptScore W2151909535C2778653478 @default.
• W2151909535 hasConceptScore W2151909535C28452662 @default.
• W2151909535 hasConceptScore W2151909535C29730261 @default.
• W2151909535 hasConceptScore W2151909535C31760486 @default.
• W2151909535 hasConceptScore W2151909535C71924100 @default.
• W2151909535 hasConceptScore W2151909535C90924648 @default.
• W2151909535 hasIssue "5" @default.
• W2151909535 hasLocation W21519095351 @default.
• W2151909535 hasOpenAccess W2151909535 @default.
• W2151909535 hasPrimaryLocation W21519095351 @default.
• W2151909535 hasRelatedWork W1911012776 @default.
• W2151909535 hasRelatedWork W1981794048 @default.
• W2151909535 hasRelatedWork W1997366816 @default.
• W2151909535 hasRelatedWork W2005605711 @default.
• W2151909535 hasRelatedWork W2072252734 @default.

• next